44 Results for "

RIPK2

" in MedChemExpress (MCE) Product Catalog:
Products (44)

44 Results for "RIPK2" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-18937
CAS No.: 1354825-58-3
Target:  

RIP kinase

Research Areas:  

Cancer

WEHI-345 is a potent and selective RIPK2 kinase inhibitor with an IC50 of 0.13 μM, which delays RIPK2 ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-107978
CAS No.: 2141969-56-2
Purity:  99.57%
Target:  

RIP kinase

Research Areas:  

Inflammation/Immunology

RIPK-IN-4 is a selective RIPK2 inhibitor with an IC50 value of 3 nM. RIPK-IN-4 can be used for the research of inflammatory diseases .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-136789
CAS No.: 2414572-47-5
Purity:  99.69%
Synonyms: BDTX-189
Target:  

EGFR

Research Areas:  

Cancer

Tuxobertinib (BDTX-189) is a potent, orally active and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations, including EGFR/HER2 exon 20 insertion mutants. Tuxobertinib shows KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-111866
CAS No.: 1801547-16-9
Purity:  99.89%
Target:  

PROTACs RIP kinase

Research Areas:  

Metabolic Disease

PROTAC RIPK degraders -2 is a non-peptide PROTAC based on von Hippel-Lindau and targets serine-threonine kinase RIPK2, which is highly selective to the degradation of RIPK2. PROTAC RIPK degrader-2 acts as an activator to increase cell death and activate ion channels in cancer cells. PROTAC RIPK degrader-2 also can inhibit protein interactions, such as receptors and ligands, involved in a variety of diseases, such as cancer and diabetes [2].
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-131064
CAS No.: 2361139-70-8
Purity:  99.19%
Target:  

RIP kinase

Research Areas:  

Inflammation/Immunology

RIPK3-IN-1 is a RIPK3 type II DFG-out inhibitor with an IC50 of 9.1 nM. RIPK3-IN-1 inhibits RIPK1 and RIPK2 with IC50s of 5.5 and >10 μM. RIPK3-IN-1 is also a c-Met kinase inhibitor with an IC50 of 1.1 μM .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-124793
CAS No.: 319492-82-5
Purity:  98.79%
Research Areas:  

Infection

GAK inhibitor 49 is a potent, ATP-competitive and highly selective cyclin G associated kinase (GAK) inhibitor with a Ki of 0.54 nM and a cell IC50 of 56 nM. GAK inhibitor 49 also shows binding to RIPK2 .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-124793A
CAS No.: 2930378-91-7
Purity:  99.52%
Research Areas:  

Infection

GAK inhibitor 49 hydrochloride is a potent, ATP-competitive and highly selective cyclin G associated kinase (GAK) inhibitor with a Ki of 0.54 nM and a cell IC50 of 56 nM. GAK inhibitor 49 hydrochloride also shows binding to RIPK2 .
loading...
    loading...
Cat. No.: HY-115630
CAS No.: 2361988-77-2
Purity:  99.82%
Research Areas:  

Cancer

cRIPGBM chloride, an orally active, proapoptotic derivative. cRIPGBM can be generated from glioblastoma multiforme (GBM) cancer stem cells (CSCs). cRIPGBM(chloride) targets to receptor-interacting protein kinase 2 (RIPK2) to induce caspase 1-dependent apoptosis. cRIPGBM(chloride) suppresses the formation of RIPK2/TAK1 (prosurvival complex), and increases the formation of RIPK2/caspase 1 (proapoptotic complex). cRIPGBM(chloride) exerts potent anti-tumor activity in vivo in animal models .
loading...
    loading...
Cat. No.: HY-19628
CAS No.: 1638644-62-8
Research Areas:  

Inflammation/Immunology

OD36 is a RIPK2 inhibitor with an IC50 of 5.3 nM. OD36 is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket. OD36 shows ALK2-directed activity with KDs of 37 nM [2].
loading...
    loading...
Cat. No.: HY-155782
CAS No.: 2772600-18-5
Purity:  99.59%
Target:  

RIP kinase

Research Areas:  

Inflammation/Immunology

Zharp2-1 is an oral effective RIPK2 inhibitor, highly associated with inflammatory bowel disease (IBD). Zharp2-1 blocker muramyl dipeptide (MDP) induces growth of mononuclear cells and induces inflammatory cell factor infection. Zharp2-1 attenuates MDP-induced small inguinal peritonitis, or ameliorates by DNBS-induced large inguinal conjunctivitis .
loading...
    loading...
Cat. No.: HY-157325
CAS No.: 2885227-09-6
Purity:  99.73%
Target:  

RIP kinase

Research Areas:  

Inflammation/Immunology

RIPK2-IN-5 (compound 14) is a high affinity and excellent selectivity RIPK2 inhibitor with an IC50 value of 5.1nM. RIPK2-IN-5 has cellular anti-inflammatory effect and can reduce the secretion of MDP-induced TNF-α with a dose-dependent manner. RIPK2-IN-5 shows moderate stability in human liver microsome. RIPK2-IN-5 can be used for the research of immune diseases .
loading...
    loading...
Cat. No.: HY-122665
CAS No.: 2000209-42-5
Purity:  98.64%
Research Areas:  

Cancer

HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM. HTH-01-091 also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 can be uesd for breast cancer research .
loading...
    loading...
Cat. No.: HY-146694
CAS No.: 2245820-70-4
RIPK2-IN-1 (compound 18f) is a potent RIPK2 inhibitor with an IC50 of 51 nM. RIPK2-IN-1 inhibits ALK2 with an IC50 of 5 nM. RIPK2-IN-1 has an IC50 of 390 nM on RIPK2/NOD2 in cell assay .
loading...
    loading...
Cat. No.: HY-157456
CAS No.: 2763831-43-0
Purity:  ≥98.0%
Target:  

RIP kinase

Research Areas:  

Inflammation/Immunology

RIPK1-IN-19 is a selective RIPK1 inhibitor (IC50=15 nM). RIPK1-IN-19 does not show obvious activity against RIPK2, RIPK3, and RIPK4. RIPK1-IN-19 displays potent protective activity in TNFα-induced systemic inflammatory response syndrome (SIRS) model and Imiquimod (IMQ)-induced psoriasis model. RIPK1-IN-19 can be used in research on inflammation and immune system diseases .
loading...
    loading...
Cat. No.: HY-147235
CAS No.: 2143956-20-9
Target:  

RIP kinase PROTACs

Research Areas:  

Infection

RIPK2-IN-2 (example 25) is a RIP2 kinase PROTAC inhibitor. RIPK2-IN-2 can block RIP2-dependent proinflammatory signaling, regulated RIP2 kinase activity in auto inflammatory diseases .
loading...
    loading...
Cat. No.: HY-136010
CAS No.: 2126803-41-4
Target:  

RIP kinase PROTACs

Research Areas:  

Inflammation/Immunology

RIP2 Kinase Inhibitor 4 is a potent and selective RIPK2 PROTAC. RIP2 Kinase Inhibitor 4 effectively degrades RIPK2 (pIC50 of 8) and inhibits the release of related TNF-α .
loading...
    loading...
Cat. No.: HY-157309
Target:  

RIP kinase

Research Areas:  

Cancer

RIPK2-IN-4 is a potent and specific RIPK2 inhibitor with an IC50 value of 5 nM .
loading...
    loading...
Cat. No.: HY-171592
CAS No.: 2789711-40-4
RIPK2-IN-7 (Compound 10w) is an orally active, selective RIPK2 inhibitor (IC50: 0.6 nM). RIPK2-IN-7 inhibits RIPK2 kinase activity, blocks the nucleotide-binding oligomerization domain (NOD) signaling pathway, and reduces the production of inflammatory factors (such as TNFα). RIPK2-IN-7 can be used in the study of inflammatory bowel disease (IBD) .
loading...
    loading...
Cat. No.: HY-RS11995
Research Areas:  

Others

RIPK2 Human Pre-designed siRNA Set A contains three designed siRNAs for RIPK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS11996
Research Areas:  

Others

Ripk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ripk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...